Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISR-DAPT: 12 vs 24 Months DAPT for In-Stent Restenosis
NCT02402491Phase 4Unknown
- Sponsor
- Beijing An Zhen Hospital
- Start
- Jan 2013
- Primary completion
- Jun 2015
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in in-stent restenosis (ISR), sponsored by Beijing An Zhen Hospital. Primary endpoint: Major Adverse Cardiac and Cerebrovascular Events at 24 months. Status: unknown.
02
Conditions
in-stent restenosis (ISR)
Beyond the preview
Go deeper on NCT02402491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02402491.